In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Food and Drug Administration (FDA) has approved YARTEMLEA® ...

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

InflaRx ( ($IFRX) ) has shared an announcement. On December 30, 2025, InflaRx reported detailed Phase 3 data analyses for vilobelimab in pyoderma ...

The firm is also calling for measures to support the green transition and the workforce Read more at The Business Times.

By Kilo MIKEGhana stands at an important crossroads in its democratic evolution. After more than three decades of relative constitutional stability, it has become increasingly clear that the current ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...

Access to capital remains one of the most persistent constraints facing entrepreneurs, investors, and institutions. Despite ...

LOUISVILLE, Ky. (WDRB) -- A new alternative designed to provide a solution for cell phone bans in the classroom, as well as student attendance and behavioral monitoring, was unveiled in Louisville on ...